Acadia Pharmaceuticals Inc. announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment ...
Coprescription of benzodiazepines and opioid agonist treatment (OAT) is associated with an increased risk for drug-related poisoning (DRP) mortality in opioid-dependent individuals ...